한 문단으로 보기
Beam was built around base editing, the technique its co-founder invented for changing one DNA letter into another without cutting the double helix. Its sickle cell therapy has finished dosing in trials with a licence application signalled for as early as the end of 2026, and its alpha-1 antitrypsin programme produced the first correction of a disease-causing mutation inside a living person.
Beam Therapeutics was founded in 2017 by David Liu, Feng Zhang and J. Keith Joung. Its portfolio spans ex vivo base editing (risto-cel for sickle cell disease) and in vivo base editing (BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type 1a). BEAM-103, an anti-CD117 antibody, aims to replace genotoxic busulfan conditioning, potentially removing the largest source of toxicity in ex vivo cell therapy.
Sources
- Beam Therapeutics · 2026
Beam Therapeutics second quarter 2026 results ↗